UK's Domainex Awarded Funding to Support Cancer Drug Research

Domainex Ltd. has been awarded a ?250,000 grant by UK’s national innovation agency to help support the development of a new drug for the treatment of several common cancers.

UK-based drug discovery company Domainex Ltd. has been awarded a ￡250,000 grant by the Technology Strategy Board - the UK’s national innovation agency - to help support the development of a new drug for the treatment of several common cancers.

Domainex’s novel drug will work by inhibiting two closely-related protein kinase enzymes, TBK1 and IKKε. Recent studies carried out by academic groups and by Domainex have shown that blocking these protein kinases will stop certain cancer cell lines from growing, suggesting that inhibitors of these enzymes can be used for the treatment of cancer. Furthermore, these enzymes are also important in some inflammatory diseases, obesity, and Type 2 diabetes.

Domainex’s initial attention will be focused on breast and ovarian cancers.